Medium-chain Fatty Acids as Adjuvant Therapy in Alzheimer’s Disease

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disorder associated with dementia, changes in judgment, attention, and problem-solving skills, as well as apraxia and cognitive impairment. It is characterized by severe cortical atrophy, accumulation of beta-amyloid plaques, and neuropil-oval neurofibrils. This condition is not limited to older adults but can also affect young people. The origin of AD lies in a protective mechanism against the lack of nutrients, hormones, and trace elements necessary for proper brain function. The presence of toxic substances such as metals, molds, biotoxins, inflammation, and diet contribute to the disease. Various treatments for AD and other neurodegenerative diseases include medium-chain fatty acids and medications such as donepezil, rivastigmine, galantamine, and memantine, which inhibit cholinesterase. The primary goals of treatment are to improve cognitive function and delay symptoms.